Analyst Price Targets — BHC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 12:19 pm | Les Sulewski | Truist Financial | $8.00 | $7.63 | TheFly | Bausch Health price target raised to $8 from $7 at Truist |
| December 8, 2025 9:25 pm | Glen Santangelo | Barclays | $8.00 | $6.82 | TheFly | Bausch Health initiated with an Equal Weight at Barclays |
| October 23, 2024 11:34 am | Douglas Miehm | RBC Capital | $10.00 | $8.07 | TheFly | Bausch Health price target raised to $10 from $8.50 at RBC Capital |
| July 25, 2024 9:08 am | Les Sulewski | Truist Financial | $7.00 | $5.69 | TheFly | Bausch Health price target lowered to $7 from $8 at Truist |
| July 10, 2024 8:13 am | Michael Freeman | Raymond James | $8.00 | $7.19 | TheFly | Bausch initiated with Market Perform on Xifaxan risk at Raymond James |
| April 29, 2024 7:39 am | David Amsellem | Piper Sandler | $9.00 | $8.78 | StreetInsider | Bausch Health Companies (BHC) PT Raised to $9 at Piper Sandler |
| April 23, 2024 6:08 am | Doug Miehm | RBC Capital | $11.00 | $8.45 | StreetInsider | Bausch Health Companies (BHC) PT Lowered to $11 at RBC Capital |
| April 11, 2024 11:29 am | Glen Santangelo | Jefferies | $16.00 | $9.28 | StreetInsider | Jefferies on BHC (BHC): 'We see this as an extremely positive outcome for BHC and removes a key barrier to executing the spin' |
| April 5, 2024 6:16 am | Doug Miehm | RBC Capital | $12.00 | $10.05 | StreetInsider | Bausch Health Companies (BHC) PT Raised to $12 at RBC Capital |
| September 9, 2022 6:34 am | — | Piper Sandler | $6.00 | $6.70 | Benzinga | Piper Sandler Maintains Neutral on Bausch Health Companies, Lowers Price Target to $6 |
Latest News for BHC
This year's Aspire Higher scholarships are awarded to six students who have been affected by dermatologic conditions. LAVAL, QC, Aug. 27, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program.
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. “Helping people see better to live better starts with tackling the challenges patients…
Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BHC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.